衰弱指标对60岁及以上子宫内膜癌女性治愈性治疗后结局的预测价值优于传统危险因素
研究纳入88例60岁及以上接受手术、化疗和放疗的I-IV期子宫内膜癌女性,评估衰弱标志物对无病生存期(DFS)的预测价值。结果显示,至少有一个基线衰弱因素的女性复发风险为无衰弱因素者的2.21倍(HR=2.21;95%CI:1.02-4.80),3年DFS分别为48%和77%(p=0.02),且衰弱标志物还预测总生存期缩短(HR=2.34;95%CI:1.08-5.03)。结论认为联合衰弱测量比年龄、肿瘤特征和合并症更能预测DFS和OS。
要点
- 至少一个衰弱因素者复发风险为无衰弱因素者的2.21倍(HR=2.21;95%CI:1.02-4.80)。
- 3年DFS无衰弱标志物者为77%,至少一个者为48%(p=0.02)。
核心结论
- 联合衰弱测量在该老年子宫内膜癌队列中比患者年龄、肿瘤特征和合并症更能预测DFS和OS。
研究设计与样本
- 纳入88例连续≥60岁、接受手术、化疗和放疗的I-IV期子宫内膜癌女性。
- 将白蛋白<3.5mg/dL、血红蛋白<10mg/dL、BMI<20kg/m²、非意愿体重下降、ECOG体能状态≥2、骨量减少或骨质疏松史及Charlson合并症评分作为衰弱标志物。
- 采用Kaplan-Meier估计和Cox比例风险模型计算DFS。
主要发现
- 中位年龄68.5岁(范围60-88岁)。
- 65/88例女性基线至少有一个衰弱因素,23/88例有两个或以上。
- 46%(40/88)女性因治疗相关毒性出现治疗延迟、调整或中断。
- 年龄(<70岁 vs. ≥70岁)未独立预测毒性或复发风险。
- 至少一个基线衰弱因素者复发风险为无衰弱因素者的2.21倍(HR=2.21;95%CI:1.02-4.80),校正年龄、分期、分级和Charlson评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if readily obtainable markers of frailty predict disease-free survival (DFS) in elderly women with endometrial cancer treated with curative intent. METHODS: 88 consecutive women≥age 60 treated with surgery, chemotherapy and radiation for stage I-IV endometrial cancer were included. We considered the following health deficits as markers of "frailty": albumin <3.5mg/dL, hemoglobin <10mg/dL, BMI<20kg/m,2 unintentional weight loss, ECOG performance status ≥2, history of osteopenia or osteoporosis and Charlson comorbidity score. Kaplan-Meier estimates and Cox proportional hazards models of DFS were calculated. RESULTS: The median age was 68.5 (range 60-88years). The majority of women (65/88) had at least one frailty factor at baseline and 23/88 had two or more. All women received radiation and chemotherapy. Treatment was delayed, modified or truncated in 46% (40/88) of women due to treatment-related toxicity. Age (< 70 vs. ≥70 y) did not independently predict toxicity or recurrence risk. Women with at least one baseline frailty factor had twice the risk of disease recurrence (HR=2.21;95% CI:1.02-4.80) when adjusted for age, stage, grade and Charlson score. The 3-year DFS was 77% in those with no frailty markers and 48% in those with at least one (p=0.02). The presence of a frailty marker also predicted shortened overall survival (HR=2.34;95% CI:1.08-5.03) irrespective of treatment administered and stage of disease. CONCLUSIONS: A combined frailty measure was a more robust predictor of DFS and OS than patient age, tumor characteristics and comorbidities in this cohort of older women with very good functional status.
引用
- Driver JA, Viswanathan AN. Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older. Gynecol Oncol. 2017. PMID: 28359689. doi:10.1016/j.ygyno.2017.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。